Welcome to GenPrice! Check out our latest updates.

Shopping Cart (0)

Your cart is empty

Add some products to get started!

Mouse 4-1BB / TNFRSF9 Protein, His Tag

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

Product Specifications

Background

4-1BB is also known as CD137, tumor necrosis factor receptor superfamily member 9 (TNFRSF9), induced by lymphocyte activation (ILA), is a co-stimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells. In addition, CD137 expression is found on dendritic cells, follicular dendritic cells, natural killer cells, granulocytes and cells of blood vessel walls at sites of inflammation. The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice. CD137 can enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, 4-1BB/4-1BBL co-stimulatory pathway has been shown to augment secondary CTL responses to several viruses, and meanwhile augment anti-tumor immunity. 4-1BB thus is a promising candidate for immunotherapy of human cancer. CD137 has been shown to interact with TRAF2.

Specifications

This protein carries a polyhistidine tag at the C-terminus. The protein has a calculated MW of 21.9 kDa. The protein migrates as 35-45 kDa under reducing (R) condition (SDS-PAGE) due to glycosylation.

Accession Number

NP_001070976.1

Expression Region

Val 24 - Leu 211

Host

HEK293

Target

4-1BB

Conjugation

Unconjugated

Tag

C-10xHis

Source

Mouse

Stability

-20°C to -70°C for 12 months in lyophilized state; -70°C for 3 months under sterile conditions after reconstitution. For long term storage, the product should be stored at lyophilized state at -20°C or lower.

Endotoxin

1.0 EU per μg

Purity

95%

Bioactivity

Immobilized Mouse 4-1BB, His Tag (Cat. No. 41B-M52H7) at 0.5 μg/mL (100 μL/well) can bind Mouse 4‑1BB Ligand, Fc Tag (Cat. No. 41L-M5257) with a linear range of 0.2-6 ng/mL (QC tested).

Format

Powder

Buffer

PBS, pH7.4

Additives

Trehalose

Molecular Weight

21.9 kDa

Additionnal Information

Please see 'Shipping-and-Payments' sheet. Website: https://www.acrobiosystems.com/support/shipping-and-payments

Shipping Conditions

RT

Storage Conditions

-20°C

Package Size

1mg*1

Host or Source

HEK293

Species

Mouse

Protein ID

NP_001070976.1

Preservative

Trehalose

Curated Selection

Explore Other Products

Discover premium biology products from our extensive collection of 20M+ items

Samalizumab (Biosimilar Reference Antibody) (MOX2)
RA0491-01 100 µg

Samalizumab (Biosimilar Reference Antibody) (MOX2)

Ask
View Details
Samalizumab (Biosimilar Reference Antibody) (MOX2)
RA0491-02 1 mg

Samalizumab (Biosimilar Reference Antibody) (MOX2)

Ask
View Details
Samalizumab (Biosimilar Reference Antibody) (MOX2)
RA0491-03 5 mg

Samalizumab (Biosimilar Reference Antibody) (MOX2)

Ask
View Details
Samalizumab (Biosimilar Reference Antibody) (MOX2)
RA0491-04 10 mg

Samalizumab (Biosimilar Reference Antibody) (MOX2)

Ask
View Details
Samalizumab (Biosimilar Reference Antibody) (MOX2)
RA0491-05 25 mg

Samalizumab (Biosimilar Reference Antibody) (MOX2)

Ask
View Details
Samalizumab (Biosimilar Reference Antibody) (MOX2)
RA0491-06 50 mg

Samalizumab (Biosimilar Reference Antibody) (MOX2)

Ask
View Details